Detalles de la búsqueda
1.
First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
Jpn J Clin Oncol
; 47(5): 385-392, 2017 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28158579
2.
A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.
Jpn J Clin Oncol
; 47(1): 39-46, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27803033
3.
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Int J Clin Oncol
; 22(1): 70-78, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27659294
4.
Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies.
Future Oncol
; 12(18): 2117-26, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27267081
5.
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Lancet Oncol
; 15(11): 1236-44, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25175099
6.
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.
Transl Lung Cancer Res
; 12(6): 1167-1184, 2023 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37425411
7.
Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Int J Clin Oncol
; 22(1): 79, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27747455
8.
Accuracy of algorithms to identify patients with a diagnosis of major cancers and cancer-related adverse events in an administrative database: a validation study in an acute care hospital in Japan.
BMJ Open
; 12(7): e055459, 2022 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35831049
9.
Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study.
Thorac Cancer
; 13(15): 2192-2200, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35768976
10.
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.
JTO Clin Res Rep
; 3(5): 100310, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35498382
11.
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.
Drug Saf
; 41(2): 229-237, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29043496
Resultados
1 -
11
de 11
1
Próxima >
>>